Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.35 |
| ▸ | TUBB | P07437 | 3/20 | 0.35 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.35 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.35 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.35 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.35 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.35 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.35 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.35 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.35 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.35 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.35 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.35 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.35 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4114610 | 0.83 | GAA (0.42) | ACHEMAPTCYP3A4CA9PTGS2 | |
| SCHEMBL210358 | 0.79 | ACHE (0.59) | ACHEMAPTCYP3A4CA9TUBB4A | |
| SCHEMBL1458395 | 0.78 | GAA (0.36) | ACHEMAPTCYP3A4HTR2AHTR2C | |
| SCHEMBL4152456 | 0.75 | PDE4B (0.42) | ACHEMAPTCA9TUBB4ATUBB | |
| SCHEMBL1458295 | 0.75 | MAPT (0.39) | MAPTCYP3A4TUBB4ATUBBTUBA3C | |
| SCHEMBL7842504 | 0.75 | ALDH1A1 (0.47) | MAPTTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5623277 | 0.74 | MAPT (0.38) | ACHEMAPTCYP3A4CA9TUBB4A | |
| SCHEMBL17912820 | 0.73 | NPSR1 (0.46) | ACHECA9TUBB4ATUBBTUBA3C | |
| SCHEMBL1458091 | 0.72 | TPMT (0.56) | MAPTCA9TUBB4ATUBBTUBA3C | |
| SCHEMBL178390 | 0.71 | ACHE (0.50) | ACHEMAPTCYP3A4CA9TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1403250-B1 | BIS(5-ARYL-2-PYRIDYL) DERIVATIVE | KOWA CO (JP) | 2007-07-18 | — | — | EP | disclosed |
| US-7196101-B2 | Bis(5-aryl-2-pyridyl) compound having excellent immunoglobulin (IgE) antibody production inhibiting activity, useful for the prevention or treatment of allergic immune diseases | KOWA CO., LTD (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20050101634-A1 | Bis(5-aeyl-2-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1403250-A1 | BIS(5-ARYL-2-PYRIDYL) DERIVATIVE | Kowa Co., Ltd. (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-6706703-B2 | BIS(5-ARYL-2-PYRIDYL) COMPOUND HAVING EXCELLENT IMMUNOGLOBULIN (IGE) ANTIBODY PRODUCTION INHIBITING ACTIVITY, USEFUL FOR THE PREVENTION OR TREATMENT OF ALLERGIC IMMUNE DISEASES | KOWA CO., LTD. (JP) | 2004-03-16 | — | — | US | disclosed |
| US-20030027814-A1 | Bis(5-aryl-2-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101634-A1 | Bis(5-aeyl-2-pyridyl) derivatives | H1-0, BRD4, PAH | ACHE 3211/4885MAPT 4297/4885CYP3A4 350/4885 |
| US-20030027814-A1 | Bis(5-aryl-2-pyridyl) derivatives | AHR, PAH, H1-0 | ACHE 4207/4885MAPT 3926/4885CYP3A4 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.